Abstract
This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years. Patients with Positive and Negative Syndrome Scale (PANSS) total scores ≥70 and ≤ 120 were randomized to receive blonanserin or risperidone using a gradual dose-titration method (blonanserin tablets: 8-24 mg/day; risperidone tablets: 2-6 mg/day), twice daily. Treatment populations consisted of 128 blonanserin-treated patients and 133 risperidone-treated patients. Intention-to-treat analysis was performed using the last observation carried forward method. Reductions of PANSS total scores by blonanserin and risperidone treatment were -30.59 and -33.56, respectively. Risperidone treatment was associated with elevated levels of serum prolactin (67.16% risperidone versus 52.31% blonanserin) and cardiac-related abnormalities (22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were more prone to extrapyramidal side effects (48.46% blonanserin versus 29.10% risperidone). In conclusion, blonanserin was as effective as risperidone for the treatment of Chinese patients with schizophrenia. The overall safety profiles of these drugs are comparable, although ...Continue Reading
References
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Jan 1, 1994·The Psychiatric Quarterly·J P LindenmayerS Grochowski
Dec 18, 2001·Biological Psychiatry·J A LiebermanJ Gilmore
Jan 3, 2007·Archives of General Psychiatry·Jonna PeräläJouko Lönnqvist
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Jul 9, 2008·Psychological Medicine·J van OsL Krabbendam
May 14, 2009·Clinical Medicine : Journal of the Royal College of Physicians of London·A J Larner
Jun 26, 2009·CNS Drugs·Esther GarciaYoshikatsu Terazawa
Nov 8, 2012·Journal of Psychiatric Research·Taro KishiNakao Iwata
Feb 8, 2014·PloS One·Taro KishiNakao Iwata
May 24, 2014·Neuropsychiatric Disease and Treatment·Pierre Chue, Justine K Lalonde
Citations
Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic
Dec 15, 2019·Human Psychopharmacology·Wenjuan YuHuafang Li
Dec 12, 2019·Psychiatry and Clinical Neurosciences·Yuan FengGang Wang
Jul 2, 2019·Experimental and Therapeutic Medicine·Lihua JiaPeiling Li
Dec 29, 2019·CNS Drugs·Nakao IwataTeruhiko Higuchi
Sep 17, 2020·The International Journal of Neuropsychopharmacology·Hironori NishibeYoshiro Okubo